公开(公告)号：US20250114394A1

公开(公告)日：2025-04-10

申请号：US18597050

申请日：2024-03-06

Applicant: RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Robert John LINHARDT ,  So-Young Kim ,  Weihua Jin ,  Jonathan Seth Dordick ,  Fuming Zhang ,  Seok-Joon Kwon ,  Paul S. Kwon ,  Keith Fraser

IPC: A61K31/727 ,  A61K31/737 ,  A61K45/06 ,  A61P31/04

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) via competitive binding to SARS-COV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-COV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-COV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

公开(公告)号：US20250090572A1

公开(公告)日：2025-03-20

申请号：US18899285

申请日：2024-09-27

Applicant: RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Robert John LINHARDT ,  So-Young Kim ,  Weihua Jin ,  Jonathan Seth Dordick ,  Fuming Zhang ,  Seok-Joon Kwon ,  Paul S. Kwon ,  Keith Fraser

IPC: A61K31/737 ,  A61K31/727 ,  A61P31/14

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.